INFINITY PHARMA
ActiveSummary
INFINITY PHARMA has been active since 1976 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €16.4m and a net result of -€231,419. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 91% of 6,039 sector peers (NACE 46, financial year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).
Directors
Board 3
2 not recently confirmed
Day-to-day management 1
2 not recently confirmed
Permanent representatives 1
Statutory auditor 1
Mandate history
- Board
- Day-to-day management
- Statutory auditor
- not recently confirmed
- began earlier
| Name | Functions and periods |
|---|---|
| Céline Caveye |
|
| Padilla Rafael |
|
| De Jong Cormelia Neeltje |
|
| Peter De Sutter |
|
| Deloitte Bedrijfsrevisoren/Réviseurs d’Entreprises |
|
| Cornelia de Jong |
|
| JAN PEETERS |
|
| Johan Verlinden |
|
| Bart Ameije |
|
| Hernando Acosta |
|
| PricewaterhouseCoopers Reviseurs d'Entreprises |
|
| Jumoo bvba |
|
| Johannes Stols |
|
| Kalman Petro |
|
| Davy De Vlieger |
|
| BOUVRY Christophe |
|
| Procuram bvba |
|
| Tim Delameilleure |
|
| Rony Lebotte |
|
| Gerardus van Jeveren |
|
| BVBA ROMANI MANAGEMENT |
|
| SCCRL PricewaterhouseCoupers |
|
Owners and capital
Owners
1 ownerChain of control
- Fagron NV
- INFINITY PHARMA
Highest known parent: Fagron NV. The sources do not say who stands above it.
Owners 1
- Fagron NVconsolidating parentconsolidates
According to the 2025 annual accounts of INFINITY PHARMA and those of the other companies, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.
Capital and shareholders
- 02-01-2026 Capital increase of €4,000,000 · to €13,300,000 · no new shares · in cash
- 23-01-2025 Capital increase of €15,009,359.36 · to €16,668,329.98 · in cash
- 23-01-2025 Capital reduction of €7,368,329.98 · to €9,300,000 · “aanzuivering van verliezen”
- 26-07-2021 Capital stated in the deed · €1,658,970.62 · 1,366,595 shares
- 10-07-2018 Capital increase of €99,873.22 · to €799,872.46 · 170,635 new shares
- 10-07-2018 Capital increase of €859,098.16 · to €1,658,970.62 · no new shares
- 30-11-2017 Capital reduction of €186,169,363.76 · to €699,999.24 · “uitkering in natura van een deel van de ... vordering”
- 05-05-2014 Capital increase of €133,977,156 · to €186,869,363 · 857,451 new shares · schuldvordering
Show 1 older capital entries
- 02-03-2010 Capital stated in the deed · €52,892,207